Myriad Genetics, Inc. MYGN
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.46% | -10.51% | 2.30% | -0.38% | -3.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.46% | -10.51% | 2.30% | -0.38% | -3.56% |
| Cost of Revenue | 5.01% | 3.92% | 1.78% | 5.53% | -2.52% |
| Gross Profit | -4.24% | -16.34% | 2.53% | -2.72% | -4.01% |
| SG&A Expenses | 8.78% | 1.59% | 0.07% | -8.60% | -0.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.94% | 1.77% | 0.36% | -6.63% | -0.91% |
| Operating Income | -71.24% | -211.20% | 12.76% | 82.66% | -30.90% |
| Income Before Tax | -66.41% | 87.11% | -15.99% | 77.24% | -23.58% |
| Income Tax Expenses | -75.00% | 700.00% | -- | -129.41% | 33.33% |
| Earnings from Continuing Operations | -60.22% | 86.93% | -34,000.00% | 81.41% | -23.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.22% | 86.93% | -34,000.00% | 81.41% | -23.98% |
| EBIT | -71.24% | -211.20% | 12.76% | 82.66% | -30.90% |
| EBITDA | -155.14% | -1,750.00% | 12.33% | 484.00% | -386.36% |
| EPS Basic | -55.86% | 87.25% | -32,981.82% | 81.84% | -21.06% |
| Normalized Basic EPS | -61.85% | -199.15% | 4.78% | 65.24% | -34.69% |
| EPS Diluted | -56.30% | 87.13% | -32,981.82% | 81.92% | -21.06% |
| Normalized Diluted EPS | -61.85% | -199.15% | 4.78% | 65.24% | -34.69% |
| Average Basic Shares Outstanding | 2.79% | 2.49% | 2.52% | 2.41% | 2.42% |
| Average Diluted Shares Outstanding | 2.79% | 2.49% | 2.52% | 2.41% | 2.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |